This Article Full Text Full Text (PDF) All Versions of this Article: 40/1/13    most recent 01.HYP.0000022570.02119.75v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baker, E. H. Articles by MacGregor, G. A. Search for Related Content PubMed PubMed Citation Articles by Baker, E. H. Articles by MacGregor, G. A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information High Blood Pressure Related Collections Clinical Studies

(Hypertension. 2002;40:13.)
© 2002 American Heart Association, Inc.

Scientific Contributions

Amiloride, a Specific Drug for Hypertension in Black People With T594M Variant?

Emma H. Baker; Ajay Duggal; Yanbin Dong; Nicola J. Ireson; Monique Wood; Nirmala D. Markandu; Graham A. MacGregor

From the Department of Physiological Medicine, St George’s Hospital Medical School, Cranmer Terrace, London, United Kingdom.

Correspondence to Dr Emma Baker, Department of Physiological Medicine, St George’s Hospital and Medical School, Cranmer Terrace, London, SW17 0RE. E-mail ebaker{at}sghms.ac.uk

The T594M polymorphism of the epithelial sodium channel is found in 5% of people of African origin and is significantly associated with high blood pressure. Although the T594M polymorphism could increase renal sodium absorption through affected channels, it is not known whether this polymorphism causes hypertension. Amiloride specifically inhibits overactive sodium channels and effectively controls blood pressure in Liddle’s syndrome, in which hypertension is caused by separate epithelial sodium channel mutations. The aim of this study was to determine whether amiloride was effective in lowering blood pressure in individuals with the T594M polymorphism. In an open, controlled study, 14 black hypertensive individuals with the T594M polymorphism were withdrawn from their usual medication and treated with amiloride. On entry to the study, individuals taking a mean of 2 drugs had blood pressure of 142/89±3/3 mm Hg. Amiloride alone (10 mg BID) controlled blood pressure effectively to the same level (140/91±4/2 mm Hg). When amiloride was withdrawn for 2 weeks, there was a large increase in blood pressure of 17/8±4/2 mm Hg (systolic, P<0.05; diastolic, P<0.01). On restarting amiloride, blood pressure was again controlled to 140/88±6/2 mm Hg. These results demonstrate that 10 mg BID amiloride is effective in controlling blood pressure in hypertensive individuals of African origin who have the T594M polymorphism. Our study supports the concept that the T594M polymorphism contributes to the elevation of blood pressure and suggests that consideration should be given to the use of amiloride in affected individuals.

Key Words: hypertension, essential • blacks • sodium channel • polymorphism • epithelium

This article has been cited by other articles:

				S. J. Hood, K. P. Taylor, M. J. Ashby, and M. J. Brown The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) Double-Blind Crossover Trial in Patients With Low-Renin Hypertension and Elevated Aldosterone-Renin Ratio Circulation, July 17, 2007; 116(3): 268 - 275. [Abstract] [Full Text] [PDF]

				J. M. Hollier, D. F. Martin, D. M. Bell, J.-L. Li, M. G. Chirachanchai, D. V. Menon, D. Leonard, X. Wu, R. S. Cooper, C. McKenzie, et al. Epithelial Sodium Channel Allele T594M Is Not Associated With Blood Pressure or Blood Pressure Response to Amiloride Hypertension, March 1, 2006; 47(3): 428 - 433. [Abstract] [Full Text] [PDF]

				J. D. Spence Letter to the Editor: Individualized Therapy for Hypertension Hypertension, March 1, 2006; 47(3): e11 - e11. [Full Text] [PDF]

				D. G. Warnock and B. C. Rossier Renal Sodium Handling: The Role of the Epithelial Sodium Channel J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3151 - 3153. [Full Text] [PDF]

				L. R. Krakoff Diuretics for Hypertension Circulation, September 6, 2005; 112(10): e127 - e129. [Full Text] [PDF]

				M. H. Weinberger More on the Sodium Saga Hypertension, November 1, 2004; 44(5): 609 - 611. [Full Text] [PDF]

				F. F. Samaha, R. C. Rubenstein, W. Yan, M. Ramkumar, D. I. Levy, Y. J. Ahn, S. Sheng, and T. R. Kleyman Functional Polymorphism in the Carboxyl Terminus of the {alpha}-Subunit of the Human Epithelial Sodium Channel J. Biol. Chem., June 4, 2004; 279(23): 23900 - 23907. [Abstract] [Full Text] [PDF]

				R. G. Hart, L. A. Pearce, S. Di Legge, J. D. Spence, A. Tamayo, V. Hachinski, D. M. Green, A. H. Ropper, R. A. Kronmal, B. M. Psaty, et al. Serum potassium level and dietary potassium intake as risk factors for stroke Neurology, June 10, 2003; 60(11): 1869 - 1871. [Full Text] [PDF]